文献速递甲状腺疾病

超声引导下射频消融治疗低风险甲状腺微小乳头状癌的疗效与安全性:一项前瞻性研究

Efficacy and Safety of Ultrasound-Guided Radiofrequency Ablation for Treating Low-Risk Papillary Thyroid Microcarcinoma: A Prospective Study.
PubMed 文献 · Thyroid · 2016-08-18

该前瞻性研究纳入92例患者共98个低风险甲状腺微小乳头状癌结节,评估超声引导下射频消融的疗效与安全性。消融后1至18个月体积缩小率逐步下降,随访期间未检出残留或复发肿瘤及可疑转移淋巴结,无主要并发症。作者认为射频消融可有效消除低风险甲状腺微小乳头状癌,或可作为治疗选择之一。

要点

  • 射频消融后1、3、6、12、18个月平均体积缩小率分别为0.47±0.27、0.19±0.16、0.08±0.11、0.04±0.10和0。
  • 6个月前各随访时间点间体积缩小率差异有统计学意义(p < 0.01),6个月与12个月后比较无显著差异(p = 0.42)。
  • 随访期间消融区及残留甲状腺组织均未检出残留或复发肿瘤,未见可疑转移淋巴结,无主要并发症。

核心结论

  • 射频消融可有效消除低风险甲状腺微小乳头状癌,并发症率很低,或可作为甲状腺微小乳头状癌的替代治疗策略。

研究设计与样本

  • 前瞻性研究,纳入92例患者共98个低风险甲状腺微小乳头状癌结节,消融前行超声及超声造影检查。
  • 采用移动 Shot 技术行射频消融,消融范围超出肿瘤边缘以防边缘残留和复发。
  • 术后1、3、6、12个月及此后每6个月随访,以超声和超声造影评估消融区。
  • 消融后3个月在消融区中心、边缘及周围甲状腺实质行超声引导下粗针穿刺活检以排除复发。

主要发现

  • 平均肿瘤体积为118.8 ± 106.9 mm3。
  • 消融后1、3、6、12、18个月平均体积缩小率分别为0.47 ± 0.27、0.19 ± 0.16、0.08 ± 0.11、0.04 ± 0.10和0。
  • 6个月前每两个随访时间点间体积缩小率差异有统计学意义(p < 0.01),6个月与12个月后比较无显著差异(p = 0.42)。
  • 所有结节中,10个(41.7%)在6个月内消退,23个(95.8%)在12个月内消退。
  • 随访期间消融区及残留甲状腺组织未检出残留或复发肿瘤,未见可疑转移淋巴结;粗针穿刺活检组织病理证实无残留或复发肿瘤;无主要并发症。

临床怎么用

  • 作者认为射频消融可有效消除低风险甲状腺微小乳头状癌且并发症率很低,或可作为甲状腺微小乳头状癌的替代治疗策略。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Papillary thyroid microcarcinoma (PTMC) has a high incidence and a good prognosis. Surgical operation for all PTMC might be an overtreatment. The objective of this study was to evaluate the efficacy and safety of ultrasound (US)-guided radiofrequency ablation (RFA) for treating low-risk PTMC. METHODS: Ninety-eight PTMC in 92 patients were included in this study. US and contrast-enhanced ultrasound (CEUS) examinations were performed before ablation. RFA was performed using the moving-shot technique. The ablation area exceeded the tumor edge to prevent marginal residue and recurrence. Patients were followed at 1, 3, 6, and 12 months and every six months thereafter. US and CEUS examinations were used to evaluate the ablation area. At three months after ablation, US-guided core-needle biopsy (CNB) was performed in the center, at the edge of the ablation area, and in the surrounding thyroid parenchyma to exclude recurrence. RESULTS: The mean tumor volume was 118.8 ± 106.9 mm3. The mean volume reduction ratio (VRR) was 0.47 ± 0.27, 0.19 ± 0.16, 0.08 ± 0.11, 0.04 ± 0.10, and 0 at 1, 3, 6, 12, and 18 months after RFA, respectively. Significant differences in the VRR were found between every two follow-up times before six months (p < 0.01), and no significant differences in the VRR were found between six months and after 12 months (p = 0.42). Of all the nodules, 10 (41.7%) resolved in six months, and 23 (95.8%) resolved in 12 months. No residual or recurrent tumor tissue was detected in RFA area or in residual thyroid tissue during follow-up. No suspicious metastatic lymph nodes were detected. The histological pathology results of US-guided CNB confirmed the absence of residual or recurrent tumor. No major complications were encountered. CONCLUSIONS: RFA can effectively eliminate low-risk PTMC with a very small complication rate. RFA may be an alternative strategy for the treatment of PTMC.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Zhang M, Luo Y, Zhang Y, et al. Efficacy and Safety of Ultrasound-Guided Radiofrequency Ablation for Treating Low-Risk Papillary Thyroid Microcarcinoma: A Prospective Study. Thyroid. 2016. PMID: 27445090

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。